No evidence of distant metastases Patients with evidence of distant metastases or leptomeningeal disease (LMD) are excluded No evidence of distant metastases Patients must have no clinical or radiological evidence of distant metastases (M) Presence of distant metastatic disease Distant metastases Patients with distant metastatic disease Have evidence of a distant metastatic disease No evidence of local recurrence or distant metastases Patients cannot have distant metastases and have to be candidates for curative re-irradiation Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax Radiographic evidence of regional or distant metastases with suspected tumor in an area that is safe to biopsy Evidence of distant metastases of stage IV Documented evidence of distant metastases No evidence of in-transit, nodal or distant metastases as determined by clinical examination, CT or MRI Prostate cancer:\r\n* Distant metastases\r\n* Lymph node metastases Presence of distant metastatic disease Documented evidence of distant metastases Patients with distant metastatic disease (prostate adjacent adenopathy is not an exclusion) Distant metastases (M disease) Unequivocal demonstration of distant metastases (M disease) Evidence of distant metastases as determined by the central reading committee Evidence of distant metastatic disease Unresectable primary tumor or regional disease or distant metastases Stage or disease without evidence of distant metastases Clinical or pathologic evidence for distant metastases Clinical or pathologic evidence for distant metastases Documented distant metastatic disease Documented evidence of distant metastases Evidence of distant metastases No evidence of distant metastases Evidence of distant metastases on any staging or imaging modality Patients with distant organ metastases will not be included in this study For patients undergoing definitive CFRT, patients with distant metastatic disease are not eligible Patients with any evidence of distant metastases Distant metastatic disease Distant metastases Evidence of distant metastases MAIN STUDY COHORT EXCLUSION CRITERIA: Evidence of nodal or distant metastases Presence of distant metastatic (M) disease Evidence of distant metastases No evidence of distant metastases Presence of distant metastatic disease The patients have documented disease beyond the peritoneal surfaces, which prevent achieving complete cytoreduction as indicated by:\r\n* Evidence of distant hematogenous metastatic disease or distant nodal metastases\r\n* Evidence of parenchymal hepatic metastases\r\n* Evidence of clinical, biochemical or radiological biliary obstruction\r\n* Evidence of gross disease of the small bowel mesentery characterized by distortion, thickening or loss of mesenteric vascular clarity which limits ability to obtain complete cytoreduction Evidence of distant metastases No evidence of distant metastatic disease Clinical evidence of regional, intransit ,or distant metastases No known local regional or distant metastatic disease Documented evidence of distant metastases Evidence of distant metastases or distant leptomeningeal metastases at the time of diagnosis Evidence of distant metastases Evidence of distant metastases (excluding para-aortic nodes) Patient with distant metastases History and/or clinical evidence of distant metastases (M) Evidence of distant metastases (below the clavicle) by clinical or radiographic measures. Stage or disease without evidence of distant metastases No evidence of distant metastases No evidence of distant metastases and measurable disease (> . cm). Patients with any evidence of distant metastases Has known distant metastases; clinically involved pelvic nodes (N-N) are allowed No evidence of distant metastatic disease Clinical evidence of local recurrence or distant metastases; Note: all patients must have either a positron emission tomography (PET)/computed tomography (CT) or a CT of chest, abdomen and pelvis and a bone scan; if one or more of these is concerning for distant metastases, follow-up imaging and/or biopsy should be performed to rule out distant metastases prior to randomization Patients with distant bone metastases at original diagnosis or relapse (patients with only skip lesions will be eligible) Distant metastases Evidence of distant metastatic disease (i.e. lung, liver, bone, brain, etc.) Evidence of distant metastases or histologically or cytologically proven lymph node metastases Distant metastases Patients with known distant metastases Documented evidence of distant metastases Evidence of distant metastases Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site; nodal, satellite/in-transit metastasis, distant metastases or disease in a prior complete lymphadenectomy basin must have been confirmed histologically by hematoxylin and eosin (H & E) stained slides Distant metastases (stage IV C, any T, any N and M) Evidence of distant metastatic disease Evidence of distant metastases (M) Clinical evidence of distant metastases per practice guidelines for breast cancer; Evidence of distant metastatic disease (Masaoka stage IVB) Isolated, distant, or non-contiguous intra-abdominal metastases, even if resected. No indication of distant metastases Distant metastases (M disease). No direct evidence of regional or distant metastases after appropriate staging studies; Presence of distant metastases Documented distant metastatic disease; NOTE: pelvic lymphadenopathy is NOT excluded Patient has evidence of distant metastases History or current radiographic or pathologic evidence of distant metastases Documented distant metastatic disease Evidence of distant metastases or histologically or cytologically proven lymph node metastases Any distant metastatic disease Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma. Distant metastatic disease, including known brain metastases Any evidence of distant metastases (M) Unequivocal demonstration of distant metastases (M disease) Patients with distant metastatic disease (Mc) will not be eligible for this study Distant metastatic disease not limited to peritoneum: solid organ metastases (liver, central nervous system, lung) Any distant metastatic disease visualized on preoperative imaging:\r\n* Solid organ metastases\r\n* Clear radiologic evidence of carcinomatosis No distant metastases Tumors considered to be unresectable due to local advancement include an absence of distant metastases as well as: Stage or disease without evidence of distant metastases Patient must not have known distant metastatic disease at presentation Evidence of distant metastatic disease. Patients with clinical, radiological/laboratory, or pathological evidence of distant metastatic disease Documented distant metastatic disease; but pelvic lymphoadenopathy is NOT excluded Radiographic evidence of regional or distant metastases with suspected tumor in an area that is safe to biopsy Patients who require radiotherapy to distant metastases during induction systemic therapy are eligible Distant metastases, including CNS and vertebral or meningeal involvement Patients with distant metastases The participant has confirmed HR+, HER-, early stage resected invasive breast cancer without evidence of distant metastases. No history of distant metastases. Evidence of distant disease or histologically-proven nodal metastases; patients with radiologic evidence of lymphadenopathy must have biopsy proof of N status Evidence of distant metastases Evidence of distant metastases (below the clavicle) by clinical or radiographic examination Prior or current evidence of any metastatic involvement of any distant site Evidence of distant metastases Tumors considered to be unresectable due to local advancement include an absence of distant metastases as well as: Documented evidence of distant metastases or brain metastases Known N nodal disease or distant metastatic disease No evidence of distant metastatic disease Patients with evidence of distant metastatic disease Have distant metastases Patients with known distant metastases or other malignancies Patients with widespread metastatic disease (> distant metastases); patients with oligometastatic disease (=< distant metastases) are allowed only if they are receiving definitive (curative) radiation therapy (RT) with or without chemotherapy Distant metastases Radiologic evidence of distant disease Patients with evidence of distant metastatic PDAC Distant metastatic disease at the time of enrollment Has distant metastases Patients with known distant metastases or other malignancies Patients who have prostate cancer with distant metastases Known distant metastatic disease No indication of distant metastases (M) Patients have no clinical evidence of distant metastatic disease Distant metastases Have regional or distant metastatic disease Clinically distant metastatic disease, either Ma/Mb/Mc Evidence of distant disease on physical exam or initial imaging Patients with nodal disease or distant metastatic disease Direct evidence of regional or distant metastases after appropriate staging studies The patient has known distant metastatic disease Subjects with any evidence of distant metastases